Přehled o publikaci
2023
Exploring the mechanisms of Venetoclax resistence via drug screening and genome-wide CRISPR screening.
LADUNGOVÁ, Adriana; Helena PESCHELOVÁ; Lenka DOSTÁLOVÁ; Yusuf LODHI; Narendra Varma GOTTUMUKKALA et al.Basic information
Original name
Exploring the mechanisms of Venetoclax resistence via drug screening and genome-wide CRISPR screening.
Authors
LADUNGOVÁ, Adriana; Helena PESCHELOVÁ; Lenka DOSTÁLOVÁ; Yusuf LODHI; Narendra Varma GOTTUMUKKALA; Jiří MAYER and Michal ŠMÍDA
Edition
The 65th ASH Annual Meeting and Exposition, San Diego, California, USA in Blood, 2023
Other information
Language
English
Type of outcome
Konferenční abstrakta
Country of publisher
United States of America
Confidentiality degree
is not subject to a state or trade secret
References:
Marked to be transferred to RIV
No
Organization
Středoevropský technologický institut – Repository – Repository
Keywords in English
BCL-2 inhibitor; acute myeloid leukemia; MCL1 upregulation
Links
MUNI/A/1330/2021, interní kód Repo. MUNI/A/1419/2021, interní kód Repo.
Changed: 6/1/2026 00:51, RNDr. Daniel Jakubík
Abstract
In the original language
Combining Venetoclax, a selective BCL-2 inhibitor, with hypomethylating agents has revolutionized frontline acute myeloid leukemia (AML) treatment. Despite its success, the occurrence of resistance remains a significant concern, limiting the range of available treatment alternatives. Little is known about the mechanism by which the cells escape the treatment. Recent studies have observed MCL1 upregulation in AML cells to promote resistance, and the rationale to use an MCL1 inhibitor became attractive. Although MCL1 inhibitors work exceptionally well in vitro their clinical trials were unsuccessful due to their toxicity. Here, we aim to identify other genes responsible for acquiring resistance and tackle the problem through screening for clinically approved drugs to rapidly benefit the patients with our study.
